JXR(01951.HK) :Narrows IVF Cycle Decline to 1.4% in 2025, Chengdu Flagship Hospital Posts 1.3% Growth
JXR Group Limited (Stock Code: 1951) issued a voluntary announcement on January 5, 2025, disclosing its key operational data for the 2025 fiscal year. The company stated, "Through continuous and unwavering optimization of operational measures, the Group's in vitro fertilization (IVF) egg retrieval cycles in the fourth quarter of 2025 saw further improvement compared to the third quarter of 2025."
According to the announcement, "Although the first half of 2025 declined by 8.0% compared to the same period in 2024, the Group's Greater China region business in 2025 still demonstrated strong resilience, with the full-year performance decreasing only 0.4% compared to 2024, having basically recovered to 2024 levels."
For the year ended December 31, 2025, the Group's overall IVF egg retrieval cycles narrowed to a decline of 1.4% (comparing full-year 2024 to full-year 2025), an improvement from the 5.2% decline (comparing the first three quarters of 2024 to the first three quarters of 2025). Specifically, the Group's Chengdu flagship hospital turned around to post a 1.3% year-over-year increase for full-year 2025, compared to a 1.9% decline in the first three quarters. Meanwhile, the Greater Bay Area's IVF cycles saw its decline narrow from 13.5% in the first three quarters of 2025 to 5.9% for the full year. The Group's U.S. and other overseas markets also showed improvement, with the decline narrowing from 10.8% in the first three quarters to 6.9% for the full year.
The announcement provided detailed figures: Chengdu region recorded 14,070 cycles in 2025, up 1.3% year-over-year; Greater Bay Area recorded 5,769 cycles, down 5.9%; Kunming and Wuhan recorded 4,242 cycles, up 1.5%; overseas markets (U.S. and Laos) recorded 4,235 cycles, down 6.9%; with a total of 28,039 cycles, representing a 1.4% year-over-year decline.
The company specifically noted, "The Company has terminated its operating business in Laos, and as of the date of this announcement, the liquidation process has been completed."
Looking ahead to 2026 and beyond, the Group "will continuously and unwaveringly enhance clinical treatment outcomes, patient care quality, and service supply levels, accelerate the iterative upgrade of core reproductive medical technologies, deepen scientific research innovation and clinical transformation in reproductive medicine, optimize medical processes and digital service systems, further consolidate the regional market position of the Chengdu flagship hospital, accelerate capacity release and market expansion following the relocation of the Greater Bay Area's new hospital campus, while actively responding to overseas policy changes and tapping into the growth potential of international markets."
The announcement concluded with a disclaimer: "The information contained in this announcement is based on the Group's preliminary assessment and information currently available to the Company, rather than based on any data or information reviewed or audited by the Company's auditor. The figures above are for reference only and do not constitute forward-looking statements or profit figures."
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
